Search research articles
Contact Us
Filters
Showing results (171-180 of 349) with videos related to
Page
of 35
Sort By:
The American Journal of Cardiology
|
September 28, 2011
Usefulness of the admission electrocardiogram to predict long-term outcomes after non-ST-elevation acute coronary syndrome (from the FRISC II, ICTUS, and RITA-3 [FIR] Trials)
Peter Damman, Lene Holmvang, Jan G P Tijssen, et al.
American Heart Journal
|
October 8, 2013
Learning from recent trials and shaping the future of acute heart failure trials
Robert J Mentz, Gary Michael Felker, Tariq Ahmad, et al.
JACC. Cardiovascular Interventions
|
February 25, 2012
Timing of angiography with a routine invasive strategy and long-term outcomes in non-ST-segment elevation acute coronary syndrome: a collaborative analysis of individual patient data from the FRISC II (Fragmin and Fast Revascularization During Instability in Coronary Artery Disease), ICTUS (Invasive Versus Conservative Treatment in Unstable Coronary Syndromes), and RITA-3 (Intervention Versus Conservative Treatment Strategy in Patients With Unstable Angina or Non-ST Elevation Myocardial Infarction) Trials
Peter Damman, Nan van Geloven, Lars Wallentin, et al.
JACC. Advances
|
January 29, 2026
Empagliflozin in Heart Failure and Previous Coronary Revascularization: Insights From EMPEROR-Pooled
Nitish K Dhingra, Javed Butler, Stefan D Anker, et al.
European Journal of Heart Failure
|
March 5, 2024
Carbohydrate antigen 125 concentrations across the ejection fraction spectrum in chronic heart failure: The EMPEROR programme
João Pedro Ferreira, Milton Packer, Naveed Sattar, et al.
JACC. Heart Failure
|
June 7, 2022
Prognostic Implications of N-Terminal Pro-B-Type Natriuretic Peptide and High-Sensitivity Cardiac Troponin T in EMPEROR-Preserved
James L Januzzi, Javed Butler, Faiez Zannad, et al.
European Heart Journal
|
December 8, 2022
Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial
Michael Bhm, Stefan Anker, Felix Mahfoud, et al.
European Journal of Heart Failure
|
September 16, 2025
Heart failure outcomes and empagliflozin effects in patients with heart failure and reduced ejection fraction in sinus rhythm or atrial fibrillation: Data from EMPEROR-Reduced
Michael Böhm, Javed Butler, Amr Abdin, et al.
European Heart Journal
|
October 26, 2012
Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies
Stuart J Pocock, Cono A Ariti, John J V McMurray, et al.
European Journal of Heart Failure
|
April 8, 2024
Insulin-like growth factor binding protein-7 concentrations in chronic heart failure: Results from the EMPEROR programme
João Pedro Ferreira, Milton Packer, Naveed Sattar, et al.
Page
of 35
Search research articles
Search
Showing results (171-180 of 349) with videos related to
Sort By:
Page
of 35
The American Journal of Cardiology
|
September 28, 2011
Usefulness of the admission electrocardiogram to predict long-term outcomes after non-ST-elevation acute coronary syndrome (from the FRISC II, ICTUS, and RITA-3 [FIR] Trials)
Peter Damman, Lene Holmvang, Jan G P Tijssen, et al.
American Heart Journal
|
October 8, 2013
Learning from recent trials and shaping the future of acute heart failure trials
Robert J Mentz, Gary Michael Felker, Tariq Ahmad, et al.
JACC. Cardiovascular Interventions
|
February 25, 2012
Timing of angiography with a routine invasive strategy and long-term outcomes in non-ST-segment elevation acute coronary syndrome: a collaborative analysis of individual patient data from the FRISC II (Fragmin and Fast Revascularization During Instability in Coronary Artery Disease), ICTUS (Invasive Versus Conservative Treatment in Unstable Coronary Syndromes), and RITA-3 (Intervention Versus Conservative Treatment Strategy in Patients With Unstable Angina or Non-ST Elevation Myocardial Infarction) Trials
Peter Damman, Nan van Geloven, Lars Wallentin, et al.
JACC. Advances
|
January 29, 2026
Empagliflozin in Heart Failure and Previous Coronary Revascularization: Insights From EMPEROR-Pooled
Nitish K Dhingra, Javed Butler, Stefan D Anker, et al.
European Journal of Heart Failure
|
March 5, 2024
Carbohydrate antigen 125 concentrations across the ejection fraction spectrum in chronic heart failure: The EMPEROR programme
João Pedro Ferreira, Milton Packer, Naveed Sattar, et al.
JACC. Heart Failure
|
June 7, 2022
Prognostic Implications of N-Terminal Pro-B-Type Natriuretic Peptide and High-Sensitivity Cardiac Troponin T in EMPEROR-Preserved
James L Januzzi, Javed Butler, Faiez Zannad, et al.
European Heart Journal
|
December 8, 2022
Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial
Michael Bhm, Stefan Anker, Felix Mahfoud, et al.
European Journal of Heart Failure
|
September 16, 2025
Heart failure outcomes and empagliflozin effects in patients with heart failure and reduced ejection fraction in sinus rhythm or atrial fibrillation: Data from EMPEROR-Reduced
Michael Böhm, Javed Butler, Amr Abdin, et al.
European Heart Journal
|
October 26, 2012
Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies
Stuart J Pocock, Cono A Ariti, John J V McMurray, et al.
European Journal of Heart Failure
|
April 8, 2024
Insulin-like growth factor binding protein-7 concentrations in chronic heart failure: Results from the EMPEROR programme
João Pedro Ferreira, Milton Packer, Naveed Sattar, et al.
Page
of 35